ProCE Banner Activity

Decitabine Plus ATRA for Newly Diagnosed MDS With Excessive Blasts

Conference Coverage
Slideset

In this report of a multicenter, open-label, randomized trial the addition of ATRA to DAC compared with DAC alone significantly improved ORR and median PFS in patients with MDS and excess blasts.

Released: December 16, 2024

Expiration: December 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation